Recombinant anti-TNFa (Adalimumab biosimilar) mAb

SOURCE: Chinese Hamster Ovary Cells (CHO) . Adalimumab belongs to the pharmacotherapeutic group –immunosuppressants, tumour necrosis factor alpha (TNF-alpha) inhibitors– (ATC code: L04AB04) . The mechanism of action of adalimumab is binding specifically to TNF-alpha and neutralising its biological function by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab is a recombinant human IgG1 monoclonal antibody composed of two kappa light chains each with a molecular weight of approximately 24 kilo Daltons (kDa) and two IgG1 heavy chains each with a molecular weight of approximately 49 kDa based on the amino acid sequence. The total molecular weight of adalimumab with post-translational modifications is approximately 148 kDa. Each light chain consists of 214 amino acid residues and each heavy chain consists of 451 amino acid residues resulting in a total of 1330 amino acids for the entire IgG1 molecule; one glycosylation site (N301) is present. The primary amino-acid sequence of the heavy and light chains is reported.

Cachectin, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor ligand superfamily member 2 (TNF-a)

TNFA

7124

P01375

Adalimumab

ELISA, WB

Greater than 98.0% as determined by SDS-PAGE.

Adalimumab is supplied as solution in 60mM Trehalose, 0.7mM L-Histidine, 0.8mM L-His-Cl, and 30gm/lit Polysorbate 20.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles.

Human IgG1, kappa